TARA - ArTara Therapeutics Inc Stock Price, Fair Value and News

3.10USD-0.64 (-17.11%)Delayed

Market Summary

USD3.10-0.64

Delayed

-17.11%

TARA Alerts

1 major insider sales recently.

CITADEL ADVISORS LLC reported owning 5.7% of TARA [2024-04-22]

TARA Stock Price

View Fullscreen

TARA RSI Chart

TARA Valuation

Market Cap

63.8M

Price/Earnings (Trailing)

-1.5

Price/Sales (Trailing)

230.26

Price/Free Cashflow

-1.82

TARA Price/Sales (Trailing)

TARA Profitability

Return on Equity

-72.72%

Return on Assets

-62.33%

Free Cashflow Yield

-54.97%

TARA Fundamentals

TARA Revenue

Revenue (TTM)

262.0K

TARA Earnings

Earnings (TTM)

-42.5M

Earnings Growth (Yr)

-22.66%

Earnings Growth (Qtr)

-8.55%

Breaking Down TARA Revenue

Last 7 days

3.3%

Last 30 days

13.6%

Last 90 days

-23.6%

Trailing 12 Months

-0.3%

How does TARA drawdown profile look like?

TARA Financial Health

Current Ratio

10.53

TARA Investor Care

Shares Dilution (1Y)

82.08%

Diluted EPS (TTM)

-3.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	449.0K	416.0K	356.0K	262.0K
2018	319.0K	379.0K	409.0K	436.0K
2017	169.0K	162.0K	199.0K	259.0K
2016	160.0K	176.0K	188.0K	193.0K
2015	2.2M	1.5M	845.0K	144.0K
2014	0	0	0	2.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ArTara Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 10, 2024	opaleye management inc.	sold	-472,424	3.1142	-151,700	-
May 09, 2024	opaleye management inc.	sold	-94,526	3.0891	-30,600	-
Jan 19, 2024	shefferman jesse	acquired	-	-	59,000	ceo and president
Jan 19, 2024	zummo jacqueline	sold (taxes)	-5,823	1.91	-3,049	chf scientific operations off
Jan 19, 2024	fabbio patrick	acquired	-	-	22,000	chief financial officer
Jan 19, 2024	zummo jacqueline	acquired	-	-	23,000	chf scientific operations off
Jan 19, 2024	shefferman jesse	sold (taxes)	-14,903	1.91	-7,803	ceo and president
Jan 19, 2024	bandari jathin	sold (taxes)	-5,498	1.91	-2,879	chief medical officer
Jan 19, 2024	fry hannah	sold (taxes)	-1,726	1.91	-904	vp, controller
Jan 19, 2024	fry hannah	acquired	-	-	8,000	vp, controller

Which funds bought or sold TARA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	added	7.44	460,028	812,830	0.09%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	69,746	69,746	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-31.78	32,926	104,051	-%
May 15, 2024	Royal Bank of Canada	added	447	15,000	16,000	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-7.81	116,910	236,590	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-21.46	32,040	79,189	-%
May 15, 2024	BAKER BROS. ADVISORS LP	unchanged	-	426,278	800,681	0.01%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-21,516	-	-%
May 15, 2024	Boxer Capital, LLC	unchanged	-	446,678	839,000	0.04%
May 15, 2024	TWO SIGMA ADVISERS, LP	unchanged	-	57,681	108,342	-%

Are Funds Buying or Selling TARA?

Are funds buying TARA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TARA

No. of Funds

TARA Alerts

1 major insider sales recently.
CITADEL ADVISORS LLC reported owning 5.7% of TARA [2024-04-22]

Unveiling ArTara Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	ra capital management, l.p.	9.99%	2,073,075	SC 13G
Apr 22, 2024	citadel advisors llc	5.7%	6	SC 13G
Apr 09, 2024	cvi investments, inc.	5.3%	600,380	SC 13G
Feb 14, 2024	orbimed advisors llc	0.0%	0	SC 13G/A
Feb 14, 2023	orbimed advisors llc	6.0%	671,741	SC 13G/A
Feb 15, 2022	perceptive advisors llc	3.8%	421,641	SC 13G/A
Feb 15, 2022	rock springs capital management lp	0.00%	0	SC 13G/A
Feb 14, 2022	ikarian capital, llc	2.5%	279,256	SC 13G/A
Feb 11, 2022	orbimed advisors llc	6.0%	671,741	SC 13G
Feb 16, 2021	perceptive advisors llc	5.4%	608,544	SC 13G/A

Recent SEC filings of ArTara Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 09, 2024	EFFECT	EFFECT
May 09, 2024	424B3	Prospectus Filed
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
May 02, 2024	S-3	S-3
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A

Peers (Alternatives to ArTara Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

ArTara Therapeutics Inc News

Latest updates

ArTara Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4
Revenue	-41.5%	31.00	53.00	73.00	105	125	113	106	92.00	98.00	83.00	46.00	32.00	38.00	46.00	53.00	56.00	33.00	34.00	37.00	1,007	1,978
Operating Expenses	7.0%	2,519	2,354	1,429	1,528	5,385	4,622	5,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	43.7%	1,804	1,255	442	450	2,722	2,268	2,240	2,294	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-34.9%	715	1,099	987	1,078	2,663	2,354	2,760	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	2.0%	-56.65*	-57.80*	-49.47*	-45.83*	-47.19*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00
EBT Margin	1.7%	-57.22*	-58.23*	-49.83*	-46.17*	-47.54*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-7.0%	-2,519	-2,354	-1,428	-1,528	-5,259	-4,510	-4,879	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-13.7%	68.00	79.00	88.00	95.00	106	113	149	155	161	173	181	189	192	203	199	63.00	70.00	40.00	10.00	12.00	18.00
Current Assets	-15.7%	58.00	69.00	78.00	84.00	95.00	86.00	99.00	101	91.00	93.00	96.00	88.00	88.00	169	167	33.00	40.00	1.00	10.00	11.00	18.00
Cash Equivalents	33.8%	53.00	40.00	34.00	34.00	21.00	24.00	48.00	35.00	26.00	36.00	41.00	48.00	59.00	169	166	30.00	36.00	1.00	2.00	3.00	4.00
Net PPE	-6.4%	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	0.00	-	0.00	0.00
Goodwill	-	-	-	-	-	-	-	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	29.00	29.00	29.00	30.00	-	-	-
Liabilities	-8.5%	10.00	11.00	12.00	10.00	12.00	11.00	9.00	9.00	9.00	11.00	10.00	10.00	4.00	4.00	4.00	4.00	5.00	3.00	2.00	2.00	3.00
Current Liabilities	-10.5%	6.00	6.00	7.00	5.00	6.00	6.00	4.00	3.00	3.00	4.00	4.00	4.00	3.00	3.00	4.00	3.00	5.00	3.00	2.00	2.00	3.00
Shareholder's Equity	-14.5%	58.00	68.00	77.00	85.00	95.00	102	139	145	152	162	170	178	188	199	195	59.00	65.00	6.00	0.00	2.00	3.00
Retained Earnings	-5.5%	-211	-200	-190	-180	-169	-159	-121	-113	-104	-94.01	-83.78	-73.01	-60.22	-46.76	-37.95	-29.98	-22.84	-12.78	-223	-222	-217
Additional Paid-In Capital	0.4%	270	269	267	266	264	263	261	260	258	256	254	252	249	246	233	89.00	88.00	11.00	211	211	210
Accumulated Depreciation	-100.0%	-	1.00	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.6%	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	18.00	-	-	-	20.00	-	-	-	74.00	-	-	-	77.00	-	-	-	6.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-19.3%	-10,379	-8,700	-6,561	-9,408	-12,888	-5,026	-5,347	-5,123	-10,961	-6,907	-6,201	-9,474	-11,920	-6,766	-3,762	-5,733	-7,146	-1,088	-1,212	-1,303	-1,406
Share Based Compensation	-15.6%	1,226	1,452	1,447	1,618	1,575	1,430	1,437	1,942	1,879	1,908	2,716	2,998	2,740	2,339	2,781	1,829	2,798	106	139	102	77.00
Cashflow From Investing	59.1%	23,100	14,518	6,378	22,351	9,860	-18,345	19,048	13,502	745	1,889	107	-1,941	-98,249	-511	-132	6.00	3,472	-45.86	-325	-76.62	-27.11
Cashflow From Financing	-Infinity%	-76.00	-	-27.00	-	-64.00	-	-18.00	-	-72.00	-	-	-	-228	10,715	139,828	-371	39,229	1*	-	-	-
Buy Backs	-	76.00	-	27.00	-	64.00	-	18.00	-	72.00	-	-	-	228	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TARA Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 7,748	$ 5,143
General and administrative	4,103	4,589
Total operating expenses	11,851	9,732
Loss from operations	(11,851)	(9,732)
Other income (expense), net:
Interest and investment income	756	687
Other income (expense), net	756	687
Net loss	$ (11,095)	$ (9,045)
Net loss per share attributable to common stockholders, basic (in Dollars per share)	$ (0.97)	$ (0.8)
Weighted-average shares outstanding, basic (in Shares)	11,420,948	11,303,869
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable debt securities	$ 30	$ 219
Other comprehensive income (loss)	30	219
Comprehensive loss	$ (11,065)	$ (8,826)

TARA Balance Sheet

2024-03-31

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 52,231	$ 39,586
Marketable debt securities	2,992	25,994
Prepaid expenses and other current assets	2,690	3,125
Total current assets	57,913	68,705
Restricted cash, non-current	745	745
Property and equipment, net	1,213	1,296
Operating lease right-of-use asset	5,018	5,264
Other assets	3,245	2,944
Total assets	68,134	78,954
Current liabilities:
Accounts payable	972	2,434
Accrued expenses and other current liabilities	3,529	2,732
Operating lease liability	1,000	983
Total current liabilities	5,501	6,149
Operating lease liability, non-current	4,227	4,484
Total liabilities	9,728	10,633
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series 1 Convertible Preferred Stock, 8,028 shares authorized at March 31, 2024 and December 31, 2023, 7,991 shares issued and outstanding as of March 31, 2024 and December 31, 2023.
Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 11,433,837 and 11,364,903 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	11	11
Additional paid-in capital	269,875	268,725
Accumulated deficit	(211,479)	(200,384)
Accumulated other comprehensive income (loss)	(1)	(31)
Total stockholders’ equity	58,406	68,321
Total liabilities and stockholders’ equity	$ 68,134	$ 78,954

About ArTara Therapeutics Inc

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York.

CEO	Mr. Jesse Shefferman
WEBSITE	protaratx.com
INDUSTRY	Biotechnology
EMPLOYEES	25

ArTara Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for ArTara Therapeutics Inc? What does TARA stand for in stocks?

TARA is the stock ticker symbol of ArTara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ArTara Therapeutics Inc (TARA)?

As of Fri May 17 2024, market cap of ArTara Therapeutics Inc is 63.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TARA stock?

You can check TARA's fair value in chart for subscribers.

What is the fair value of TARA stock?

You can check TARA's fair value in chart for subscribers. The fair value of ArTara Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ArTara Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TARA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ArTara Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TARA is over valued or under valued. Whether ArTara Therapeutics Inc is cheap or expensive depends on the assumptions which impact ArTara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TARA.

What is ArTara Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TARA's PE ratio (Price to Earnings) is -1.5 and Price to Sales (PS) ratio is 230.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TARA PE ratio will change depending on the future growth rate expectations of investors.